SynthesisMolecular psychiatry2023
Meta-analytic prevalence of comorbid mental disorders in individuals at clinical high risk of psychosis: the case for transdiagnostic assessment.
Synthesis in Molecular psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 4 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Basic Self-disorders Across Psychiatric Diagnoses and Risk Syndromes: An Updated Meta-analysis.Schizophrenia bulletin · 2026Pooled it
- Eating disorders and disordered eating symptoms in individuals at clinical high risk for psychosis: a systematic review and meta-analysis.Eating and weight disorders : EWD · 2024Pooled it
- Long-term outcomes of additional surgery versus surveillance-only clinical decision for early colorectal cancer patients after non-curative endoscopic resection: a meta-analysis.BMC gastroenterology · 2024Pooled it
- Network Meta-Analysis Indicates Superior Effects of Omega-3 Polyunsaturated Fatty Acids in Preventing the Transition to Psychosis in Individuals at Clinical High-Risk.The international journal of neuropsychopharmacology · 2024Pooled it
- Optimizing Health for Canadian Youth at Clinical High Risk for Psychosis: A Feasibility Study: Optimiser la santé des jeunes Canadiens présentant un risque clinique élevé de psychose : Une étude de faisabilité.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2026Trial
- Impact of the Unified Protocol on Attenuated Psychotic Symptoms, Cognitive Biases and Cognitive Insight in Patients at Ultra High Risk (UHR) for Psychosis: Secondary Results of a Pilot Randomized Controlled Trial.Journal of clinical psychology · 2026Trial
- Clinical predictors of at-risk mental states in general adolescent population: a 2-year follow-up study.European child & adolescent psychiatry · 2026Article
- Suicide and Self-Harm Risk in Young People at Clinical High Risk of Psychosis: Exploring Comorbid Risk Factors and Potential Points for Intervention.Schizophrenia bulletin · 2026Article
- Psychosis Mental Health Campaigns: A Scoping Review of Strategies and Outcomes.Early intervention in psychiatry · 2026Article
- Transdiagnostic profiles of socio-affective functioning in adolescents at-risk of poor mental health.JCPP advances · 2026Article
- Value representation in youth psychopathology: evidence of a transdiagnostic risk mechanism for psychosis.Translational psychiatry · 2026Article
- Real-world comprehensive care of people living with schizophrenia: recommendations across different settings and clinical stages.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026Article
- Accelerating Access to Early Intervention Through Hospital-Wide Outreach and Enhanced Referral Support.Early intervention in psychiatry · 2026Article
- Outreach and Support in South London for Bipolar At-Risk States: pilot implementation of a specialist preventive service for adolescents and young adults at risk of developing bipolar disorders.Frontiers in psychiatry · 2026Article
- Predicting the risk of mental disorders using complete blood count indicators: a machine learning approach.Frontiers in medicine · 2026Article
- Transdiagnostic prevention in youth mental health, Part II: interventions.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- The triglyceride-glucose index in relation to psychotic symptoms in adolescents with major depressive disorder.Frontiers in psychiatry · 2026Article
- Article
- Age-stratified comparison of psychopathological characteristics between psychiatric and psychological outpatients.BMC psychiatry · 2025Article
- Revisiting the Defeatist Performance Belief Scale in Adults With Schizophrenia and Youth at Clinical High-Risk for Psychosis: A Comprehensive Psychometric Analysis.Schizophrenia bulletin · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 5 countries.
Funding
Abstract
Comorbid mental disorders in subjects at clinical high risk for psychosis (CHR-P) may impact preventive care. We conducted a PRISMA/MOOSE-compliant systematic meta-analysis, searching PubMed/PsycInfo up to June 21st, 2021 for observational studies/randomized controlled trials reporting on comorbid DSM/ICD-mental disorders in CHR-P subjects ( protocol ). The primary and secondary outcomes were baseline and follow-up prevalence of comorbid mental disorders. We also explored the association of comorbid mental disorders compared with CHR-P versus psychotic/non-psychotic control groups, their impact on baseline functioning and transition to psychosis. We conducted random-effects meta-analyses, meta-regression, and assessed heterogeneity/publication bias/quality (Newcastle Ottawa Scale, NOS). We included 312 studies (largest meta-analyzed sample = 7834, any anxiety disorder, mean age = 19.98 (3.40), females = 43.88%, overall NOS > 6 in 77.6% of studies). The prevalence was 0.78 (95% CI = 0.73-0.82, k = 29) for any comorbid non-psychotic mental disorder, 0.60 (95% CI = 0.36-0.84, k = 3) for anxiety/mood disorders, 0.44 (95% CI = 0.39-0.49, k = 48) for any mood disorders, 0.38 (95% CI = 0.33-0.42, k = 50) for any depressive disorder/episode, 0.34 (95% CI = 0.30-0.38, k = 69) for any anxiety disorder, 0.30 (95% CI 0.25-0.35, k = 35) for major depressive disorders, 0.29 (95% CI, 0.08-0.51, k = 3) for any trauma-related disorder, 0.23 (95% CI = 0.17-0.28, k = 24) for any personality disorder, and <0.23 in other mental disorders (I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.